Navigation Links
Mirati Therapeutics Appoints Marcy Graham Vice President, Investor Relations and Corporate Communications
Date:1/8/2016

SAN DIEGO, Jan. 8, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Marcy Graham has been appointed Vice President, Investor Relations (IR) and Corporate Communications. As a seasoned communicator, Ms. Graham has more than 15 years of experience in the biopharmaceutical sector with expertise in growth companies and related transitions, such as the management of IPOs, financings and M&A activities, commercial product launches, and clinical development programs.

"Marcy brings substantial IR and communications expertise, and has a proven track record for building corporate brands and successfully integrating financials and marketing communications," said Charles M. Baum, M.D., Ph.D., president and CEO of Mirati. "She is a seasoned professional who will add significant value to Mirati as we advance our clinical programs." 

Before joining Mirati, Ms. Graham was Vice President, Investor Relations and Corporate Communications at aTyr Pharma, participating in two major financings including their IPO in 2015. Previously, Ms. Graham served as head of Investor Relations and Corporate Communications at Ambit Biosciences until their acquisition by Daichi Sankyo in late 2014. Ms. Graham has extensive previous experience within other biopharmaceutical companies, including senior roles at Sequenom, Inc., and Genoptix, Inc.

About Mirati Therapeutics
Mirati Therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. Mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. The Mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. Mirati is advancing three drug candidates through clinical development for multiple oncology indications. More information is available at www.mirati.com.

Forward Looking Statements
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, contain "forward-looking" statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve significant risks and uncertainties. For more detailed disclosures and discussions regarding such forward looking statements, please refer to Mirati's filings with the U.S. Securities and Exchange Commission ("SEC"), including without limitation Mirati's filings on Forms 10-K, 10-Q, and 8-K. Forward looking statements are based on the current expectations of management and upon what management believes to be reasonable assumptions based on information currently available to it. Such statements can usually be identified by the use of words such as "may," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology, or by statements that certain actions, events or results "may" or "would" be taken, occur or be achieved. Such statements include, but are not limited to, statements regarding Mirati's development plans and timelines, potential regulatory actions, expected use of cash resources, the timing and results of clinical trials, and the potential benefits of and markets for Mirati's product candidates. Forward looking statements involve significant risks and uncertainties and are neither a prediction nor a guarantee that future events or circumstances will occur. Such risks include, but are not limited to, potential delays in development timelines or negative clinical trial results, reliance on third parties for development efforts, changes in the competitive landscape, changes in the standard of care, as well as other risks described in Mirati's filings with the SEC. We are including this cautionary note to make applicable, and to take advantage of, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 for forward-looking statements. The information in this news release is given as of the date above and Mirati expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

 


'/>"/>
SOURCE Mirati Therapeutics, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Mirati Therapeutics Initiates Glesatinib (MGCD265) Phase 2 Trial In Non-Small Cell Lung Cancer (NSCLC)
2. Foundation Medicine And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib (MGCD265) In Non-Small Cell Lung Cancer (NSCLC)
3. Mirati Therapeutics Reports Third Quarter 2015 Financial Results And Provides Business Update
4. Mirati Therapeutics Presents Interim Clinical Data From Ongoing MGCD516 Phase 1 Dose Escalation Study In Patients With Advanced Solid Tumors
5. Mirati Therapeutics To Present Preclinical And Clinical Data At The IASLC 16th World Conference On Lung Cancer
6. Mirati Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update
7. Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
8. Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference
9. Mirati Therapeutics to Provide Updates on Pipeline Programs at 2015 ASCO Annual Meeting
10. Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update
11. Mirati Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2020)... ... 2020 , ... In order to provide continuous patient care ... addition to in-person visits. The San Diego-based leader in regenerative health therapies made ... professionals, and the community at large is the top priority. , Aspire ...
(Date:3/28/2020)... , ... March 27, 2020 , ... Known for bridging ... May Real has launched a new hand sanitizer in response to the COVID-19 outbreak. ... sanitizer market will continue to expand during the next several months even in the ...
(Date:3/28/2020)... ... 28, 2020 , ... TriageLogic, a leader in remote patient communication and nurse ... virtual call center that hospitals, medical organizations, and health centers can use for patient ... they are looking for a system that can be quickly deployed for staff and ...
Breaking Medicine Technology:
(Date:3/19/2020)... ... , ... Therapies of The Rockies has Colorado’s back, and they are here ... telepractice patients across the country, as remote therapy services have no geographic boundaries. Reach ... your services safely! , Therapies of The Rockies is a Denver-area speech, language, occupational, ...
(Date:3/19/2020)... ... March 19, 2020 , ... Sucheta ... Executive Function, shares a free Student Learning Exercise: ExQ® Superpower Hour. ... teachers are seeking resources to help with the immediate need for activities that ...
(Date:3/19/2020)... ... March 19, 2020 , ... Van Dyk Health Care, which sold ... Caring, on October 3, 2018 and is not involved in the operations of these ... Family of Caring at Montclair. , “We are devastated to learn about the recent ...
(Date:3/19/2020)... , ... March 20, 2020 , ... With ICH E8(R1) ... trials will look different than they do today. Be ready to implement the new ... management report shows readers how to leverage the revised guidelines’ quality-by-design approaches, expanded study ...
(Date:3/16/2020)... MONROE, La. (PRWEB) , ... March 16, 2020 ... ... through the agency's clinics and offices, Northeast Delta Human Services Authority is implementing ... is the health and safety of our clients and staff," said Dr. Monteic ...
Breaking Medicine News(10 mins):